Sareum (LON:SAR) Shares Up 12.2% – What’s Next?

Sareum Holdings plc (LON:SAR) rose 12.2% on Thursday . The company traded as high as GBX 23.89 and last traded at GBX 23. Approximately 310,180 shares changed hands during mid-day trading, an increase of 40% from the average daily volume of 221,107 shares. The stock had previously closed at GBX 20.50.

Sareum Stock Performance

The firm has a market capitalization of £33.14 million, a P/E ratio of -6.15 and a beta of -1.08. The stock has a fifty day moving average price of GBX 18.71 and a two-hundred day moving average price of GBX 16.86.

Sareum (LON:SAR) last issued its quarterly earnings results on Thursday, March 12th. The company reported GBX (1.20) earnings per share for the quarter. As a group, research analysts anticipate that Sareum Holdings plc will post -3.8 earnings per share for the current fiscal year.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.